Overview

The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
A Phase 1, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study of HEC88473 in healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
Dongguan HEC Biopharmaceutical R&D Co., Ltd.